News

July 2014: International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

Four nonprofit organizations, the Muscular Dystrophy Association (USA), Joining Jack Foundation (UK), The Duchenne Research Fund (UK) and the Duchenne Children’s Trust (UK) have joined together to provide Phase 1 clinical trial funding for the first-in-human studies of VBP15, the lead compound of ReveraGen BioPharma for Duchenne muscular dystrophy. The $2M funding is under a coordinated venture philanthropy model, providing return on investment based upon future drug sales.
More >